USFDA issues warning letter to Cipla for Goa manufacturing facility

Drug firm Cipla Ltd on Wednesday said that the US health regulator has issued a warning letter to the company for its manufacturing facility in Goa.

"Further to our earlier communication on the Goa manufacturing facility inspection conducted from September 16-27, 2019 by the United States Food and Drug Administration (USFDA), the company has received a warning letter from USFDA," Cipla Ltd said in a regulatory filing.

The company further said that it remains committed to maintain highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Shares of Cipla were trading at Rs 418.30 a piece on BSE in the morning trade on BSE, down 1.66 per cent from its previous close.